The pharmaceutical industry invests a significant portion of its revenues in research and development (R&D) activities although majority of the investment does not bring expected returns.

Projected returns on R&D investment for the top 12 pharmaceutical companies fell to 1.8% in 2019, which is the lowest level since 2010, according to GlobalData. Further, the average peak drug sales declined to $376m during the same year.

Rising cost of drug development

Rising cost of drug development, high attrition rate for pipeline products and increase in average clinical cycle are the primary causes for the decrease in R&D returns for pharmaceutical companies.

The average cost to bring a drug to market, for example, increased by 25% between 2015 and 2019 from $1.58bn to 1.98bn, according to GlobalData. Approximately 38% of companies surveyed by GlobalData believe that R&D departments will benefit the most from digital transformation.

The pharmaceutical industry has been relatively slow in adopting digital technologies although the pandemic has showcased how digital transformation can be quickly achieved. Pharmaceutical companies are turning to emerging technologies as a key tool to streamline operating models and improve the productivity and effectiveness of their R&D activities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Digital transformation is also expected to help the pharma industry to overcome existing and long-term business challenges and thrive in a challenging business landscape.

The analysis is based on the assessment of data from Deloitte and GlobalData research.